标题
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 16, Issue 9, Pages 22976-22988
出版商
MDPI AG
发表日期
2015-09-24
DOI
10.3390/ijms160922976
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent
- (2015) Chen Li et al. CANCER BIOLOGY & THERAPY
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations
- (2015) Katsuhiko Nosho et al. NEOPLASIA
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
- (2014) B A Wilky et al. BRITISH JOURNAL OF CANCER
- Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
- (2014) Jatin Roper et al. CANCER LETTERS
- KRASstatus and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis
- (2014) W. Li et al. Colorectal Disease
- Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies
- (2014) Dandan Cui et al. MOLECULAR BIOLOGY REPORTS
- Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
- (2014) Todd M. Pitts et al. PLoS One
- Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9
- (2014) Jifu E et al. TUMOR BIOLOGY
- Sequencing of treatment in metastatic colorectal cancer: Where to fit the target
- (2014) Sally Temraz WORLD JOURNAL OF GASTROENTEROLOGY
- PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
- (2013) Carolyn D. Britten CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
- (2013) S. A. Flanigan et al. CLINICAL CANCER RESEARCH
- Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
- (2013) A. Spreafico et al. CLINICAL CANCER RESEARCH
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of Novel Insulin-Like Growth Factor-1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics
- (2013) Meizhong Jin et al. ACS Medicinal Chemistry Letters
- Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
- (2012) Benjamin Blaser et al. BMC CANCER
- The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
- (2012) E J Haagensen et al. BRITISH JOURNAL OF CANCER
- Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
- (2012) S. V. Holt et al. CANCER RESEARCH
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
- (2012) A. B. Turke et al. CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
- (2011) J. Jing et al. MOLECULAR CANCER THERAPEUTICS
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- Resistance to MEK Inhibitors: Should We Co-Target Upstream?
- (2011) P. I. Poulikakos et al. Science Signaling
- Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy
- (2010) Ker Yu et al. CANCER BIOLOGY & THERAPY
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
- (2010) T. M. Pitts et al. CLINICAL CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
- (2010) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
- (2010) Christophe Frémin et al. Journal of Hematology & Oncology
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer
- (2010) J. J. Tentler et al. MOLECULAR CANCER THERAPEUTICS
- Combined Inhibition of MEK and mTOR Signaling Inhibits Initiation and Progression of Colorectal Cancer
- (2009) Yan-Jie Zhang et al. CANCER INVESTIGATION
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
- (2009) Kathryn Balmanno et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
- (2008) Tsuneo Ikenoue et al. EMBO JOURNAL
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started